Literature DB >> 11913985

Immune pathophysiology of autoimmune thrombocytopenic purpura.

J W Semple1.   

Abstract

Chronic autoimmune thrombocytopenic purpura (AITP) is an immune-mediated, bleeding disorder in which platelets are opsonized by autoantibodies and prematurely destroyed by phagocytic cells in the reticuloendothelial system. It is classed as an organ-specific autoimmune disease primarily mediated by immunoglobulin G (IgG) autoantibodies and its etiology appears to be similar to that observed for other organ-specific autoimmune diseases. Th1 cells are important in the process, and the costimulation of Th1 cells and B cells takes place in a cytokine milieu that is reminiscent of a proinflammatory process. Chronic AITP has classically been treated with nonspecific, immunosuppressive regimens (e.g., steroids). One of the most significant developments in the treatment of AITP in the last 20 years has been the use of intravenous immunoglobulin (IVIg) and anti-D preparations. These treatments confer benefit to patients with AITP by significantly raising platelet counts. Despite this, their exact mechanisms of action remain elusive. This review focuses on cell-mediated and cytokine abnormalities within AITP, and presents data related to the mechanism of action of anti-D. Copyright 2002, Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11913985     DOI: 10.1054/blre.2001.0172

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  15 in total

1.  Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura.

Authors:  Jin Yu; Susanne Heck; Vivek Patel; Jared Levan; Yu Yu; James B Bussel; Karina Yazdanbakhsh
Journal:  Blood       Date:  2008-04-17       Impact factor: 22.113

2.  Direct B-cell stimulation by peripheral blood monocyte-derived dendritic cells in idiopathic thrombocytopenic purpura patients.

Authors:  Zhenhai Zhou; Xiaoyin Li; Juan Li; Chang Su; Lan Zhuang; Shaokai Luo; Ling Zhang
Journal:  J Clin Immunol       Date:  2010-07-14       Impact factor: 8.317

3.  Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?

Authors:  Vinayakumar Siragam; Davor Brinc; Andrew R Crow; Seng Song; John Freedman; Alan H Lazarus
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

Review 4.  Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases.

Authors:  Shi-Yang Guan; Rui-Xue Leng; Muhammad Imran Khan; Humera Qureshi; Xiang-Pei Li; Dong-Qing Ye; Hai-Feng Pan
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

5.  Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia.

Authors:  Shuang Yu; Chuanfang Liu; Lanhua Li; Tian Tian; Min Wang; Yu Hu; Cunzhong Yuan; Lei Zhang; Chunyan Ji; Daoxin Ma
Journal:  Lab Invest       Date:  2014-12-08       Impact factor: 5.662

Review 6.  Refractory idiopathic immune thrombocytopenic purpura in children: current and future treatment options.

Authors:  Paul Imbach
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 7.  Idiopathic thrombocytopenic purpura: a retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol.

Authors:  Emmanuel Andrès; Jacques Zimmer; Esther Noel; Georges Kaltenbach; Argyro Koumarianou; Frédéric Maloisel
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  [Autoimmune thrombocytopenia, neutropenia and hemolysis].

Authors:  A Greinacher; J Bux; A Salama
Journal:  Internist (Berl)       Date:  2009-03       Impact factor: 0.743

9.  Repeated courses of rituximab in chronic ITP: Three different regimens.

Authors:  Aisha Hasan; Marc Michel; Vivek Patel; Roberto Stasi; Susanna Cunningham-Rundles; John P Leonard; James Bussel
Journal:  Am J Hematol       Date:  2009-10       Impact factor: 10.047

10.  Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway.

Authors:  Andrew R Crow; Honghui Yu; Dongji Han; Alan H Lazarus
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.